Humana Inc (HUM) Position Lifted by Nachman Norwood & Parrott Inc

Nachman Norwood & Parrott Inc increased its position in Humana Inc (NYSE:HUM) by 5.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,058 shares of the insurance provider’s stock after acquiring an additional 50 shares during the quarter. Nachman Norwood & Parrott Inc’s holdings in Humana were worth $281,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Keybank National Association OH raised its holdings in Humana by 1.7% in the 4th quarter. Keybank National Association OH now owns 2,259 shares of the insurance provider’s stock worth $647,000 after acquiring an additional 37 shares during the period. One Wealth Advisors LLC boosted its position in Humana by 5.8% in the fourth quarter. One Wealth Advisors LLC now owns 731 shares of the insurance provider’s stock valued at $209,000 after buying an additional 40 shares in the last quarter. Proficio Capital Partners LLC boosted its position in Humana by 81.4% in the fourth quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock valued at $31,000 after buying an additional 48 shares in the last quarter. ClariVest Asset Management LLC boosted its position in Humana by 9.5% in the fourth quarter. ClariVest Asset Management LLC now owns 635 shares of the insurance provider’s stock valued at $182,000 after buying an additional 55 shares in the last quarter. Finally, Archford Capital Strategies LLC boosted its position in Humana by 2.7% in the fourth quarter. Archford Capital Strategies LLC now owns 2,376 shares of the insurance provider’s stock valued at $681,000 after buying an additional 63 shares in the last quarter. Hedge funds and other institutional investors own 94.52% of the company’s stock.

HUM has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Thursday, December 13th. JPMorgan Chase & Co. raised shares of Humana from a “neutral” rating to an “overweight” rating and set a $283.00 target price for the company in a research note on Thursday, December 20th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $325.00 target price on shares of Humana in a research note on Wednesday, January 2nd. Barclays reaffirmed a “buy” rating and issued a $351.00 target price on shares of Humana in a research note on Sunday, January 6th. Finally, Cowen raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $275.02 target price for the company in a research note on Friday, January 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Humana has a consensus rating of “Buy” and a consensus price target of $355.06.

In other news, insider Christopher H. Hunter sold 15,586 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $305.24, for a total value of $4,757,470.64. Following the completion of the transaction, the insider now owns 28,100 shares in the company, valued at $8,577,244. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Roy A. Beveridge sold 8,278 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total transaction of $2,542,670.48. Following the completion of the transaction, the insider now owns 12,409 shares of the company’s stock, valued at approximately $3,811,548.44. The disclosure for this sale can be found here. 0.54% of the stock is currently owned by corporate insiders.

NYSE:HUM traded down $5.76 during trading hours on Thursday, hitting $260.74. The stock had a trading volume of 2,114,360 shares, compared to its average volume of 1,140,465. Humana Inc has a one year low of $255.38 and a one year high of $355.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.68 and a current ratio of 1.68. The company has a market capitalization of $36.15 billion, a PE ratio of 17.92, a PEG ratio of 1.13 and a beta of 0.93.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, February 6th. The insurance provider reported $2.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.53 by $0.12. Humana had a net margin of 2.96% and a return on equity of 19.64%. The firm had revenue of $14.17 billion during the quarter, compared to the consensus estimate of $14.04 billion. During the same quarter in the prior year, the firm earned $2.06 earnings per share. The business’s quarterly revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts forecast that Humana Inc will post 17.49 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Friday, March 29th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.84%. The ex-dividend date of this dividend is Thursday, March 28th. This is an increase from Humana’s previous quarterly dividend of $0.50. Humana’s dividend payout ratio is presently 3.44%.

WARNING: “Humana Inc (HUM) Position Lifted by Nachman Norwood & Parrott Inc” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.wkrb13.com/2019/04/11/humana-inc-hum-position-lifted-by-nachman-norwood-parrott-inc.html.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: How Do You Calculate Return on Investment (ROI)?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.